Activity – Talk Bio

Solventum Appoints Heather Knight as Chief Commercial Officer

4 days ago talkbio0Tagged Appointments, Chief Commercial Officer, Chris Barry, Dental Solutions, Global commercial operations, Health Information Systems, Heather Knight, Leadership, MedSurg, medtech, R&D, Solventum

Solventum; Heather Knight; Chief Commercial Officer; MedTech; Leadership appointment; Chris Barry; MedSurg; Dental Solutions; Health Information Systems; Global commercial operations; R&D

Epiminder Appoints Mark McLellan as Chief Financial Officer

4 days ago talkbio0Tagged Appointments, authorization, CFO, Epilepsy, Epiminder, healthcare finance, Mark McLellan, medical device company, Minder system, Preventive monitoring, United States Food and Drug Administration

Epiminder; Mark McLellan; CFO appointment; epilepsy monitoring; Minder system; FDA authorization; healthcare finance; medical device company

Inspira Technologies Appoints Former Johnson & Johnson Executive as VP of Global Sales

4 days ago talkbio0Tagged Appointments, Arginine Vasopressin-Neurophysin II Preproprotein, board of directors, commercialization, global sales, Health care facility, Inspira Technologies, Johnson & Johnson, Leadership, Mike Hershkovitz

Inspira Technologies; Mike Hershkovitz; Johnson & Johnson; VP of Global Sales; leadership appointment; healthcare; commercialization; board of directors

Connecticut Biotech Veradermics Secures $150M for Phase 3 Trials of Oral Rogaine

1 week ago talkbio0Tagged Biotechnology, Clinical Development, Clinical Trials, Connecticut biotech, Fund Raising, hair loss treatment, Oral cavity, Phase 3, Rogaine, Veradermics

Veradermics; Connecticut biotech; oral Rogaine; Phase 3 clinical trials; fundraising; hair loss treatment; biotechnology; clinical development

Former FDA Deputy Dr. Namandjé N. Bumpus to Lead Charles River’s New Scientific Advisory Board

1 week ago talkbio0Tagged alternative testing, Animal Welfare, biopharmaceutical innovation, Charles River Laboratories, Drug Development, Namandjé Bumpus, NAMs, New Approach Methodologies, Scientific Advisory Board, United States Food and Drug Administration

Namandjé Bumpus; Charles River Laboratories; Scientific Advisory Board; FDA; New Approach Methodologies; NAMs; alternative testing; drug development; animal welfare; biopharmaceutical innovation

Geron Corporation Announces Executive Leadership Transitions and Appointments

2 weeks ago talkbio0Tagged Ahmed ElNawawi, Andrew Grethlein, Appointments, commercial strategy, departures, executive leadership, Geron Corporation, Harout, Rytelo, Semerjian

Geron Corporation; executive leadership; appointments; departures; commercial strategy; RYTELO; Harout Semerjian; Ahmed ElNawawi; Andrew Grethlein; Jim Ziegler

Satellos Advances Duchenne Pill Trial in Children; Idorsia Raises $81 Million

2 weeks ago talkbio0Tagged Child, Fund Raising, Idorsia, Indonesian language, Muscular Dystrophy, Duchenne, oral small-molecule therapy, Phase 2 clinical trial, SAT-3247, Satellos, Submission, United States Food and Drug Administration

Satellos; Duchenne muscular dystrophy; SAT-3247; Phase 2 clinical trial; children; FDA IND submission; oral small-molecule therapy; Idorsia; fundraising; biotech

GSK Appoints Luke Miels as New CEO, Succeeding Emma Walmsley on Jan. 1, 2026

4 weeks ago talkbio0Tagged Appointments, CEO, Emma Walmsley, Leadership Transition, Luke Miels, R&D pipeline, SmithKline Beecham, specialty medicines, Vaccines

GSK; Luke Miels; Emma Walmsley; CEO appointment; pharmaceuticals; leadership transition; specialty medicines; vaccines; R&D pipeline

Merck Moves All R&D Operations Out of UK, Citing Unfavorable Environment

1 month ago talkbio0Tagged Biological Science Disciplines, Brexit impact, Drug Discovery, Government, Investments, layoffs, London Bioscience Innovation Centre, Merck, Multiple Sulfatase Deficiency Disease, Relocation of home or business, UK

Merck; MSD; R&D relocation; UK life sciences; drug discovery; Brexit impact; London Bioscience Innovation Centre; Francis Crick Institute; government investment; layoffs

Pfizer Veteran Suneet Varma Named CEO of Phase 3-Ready Biotech Startup Intent Biologics

2 months ago talkbio0Tagged Appointments, biotech startup, CEO, Clinical Trials, Immunology, Inflammation, Intent Biologics, Pfizer vet, Phase 3, Regenerative Medicine, Suneet Varma

Suneet Varma; Pfizer vet; Intent Biologics; CEO appointment; regenerative medicine; Phase 3 clinical trials; biotech startup; inflammation and immunology